UPDATE: Raymond James Upgrades Jounce Therapeutics (JNCE) to Strong Buy, 'Banging Table on LILRB/ILT Thesis'
Tweet Send to a Friend
(Updated - May 6, 2022 5:24 AM EDT)
Raymond James analyst Steven Seedhouse upgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Steven Seedhouse upgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
